Immune Design Corp. (NASDAQ:IMDZ) – Investment analysts at Leerink Swann increased their FY2017 EPS estimates for Immune Design Corp. in a research note issued to investors on Wednesday. Leerink Swann analyst J. Chang now expects that the biotechnology company will post earnings per share of ($1.81) for the year, up from their previous estimate of ($2.54). Leerink Swann also issued estimates for Immune Design Corp.’s Q4 2017 earnings at ($0.34) EPS and FY2018 earnings at ($1.38) EPS.

A number of other analysts have also commented on IMDZ. Zacks Investment Research raised Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a report on Tuesday, July 18th. BidaskClub lowered Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. ValuEngine raised Immune Design Corp. from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Royal Bank Of Canada assumed coverage on Immune Design Corp. in a report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, Wells Fargo & Company lowered Immune Design Corp. from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $29.00 to $10.00 in a report on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $13.19.

TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.watchlistnews.com/fy2017-eps-estimates-for-immune-design-corp-imdz-increased-by-analyst/1684369.html.

Shares of Immune Design Corp. (NASDAQ IMDZ) opened at $4.45 on Monday. Immune Design Corp. has a twelve month low of $3.78 and a twelve month high of $13.05.

Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.11. The firm had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.62 million. Immune Design Corp. had a negative return on equity of 68.69% and a negative net margin of 619.62%.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC grew its holdings in Immune Design Corp. by 170.0% during the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock valued at $760,000 after purchasing an additional 70,351 shares during the period. Nationwide Fund Advisors grew its holdings in Immune Design Corp. by 1,198.0% during the second quarter. Nationwide Fund Advisors now owns 137,709 shares of the biotechnology company’s stock valued at $1,343,000 after purchasing an additional 127,100 shares during the period. Victory Capital Management Inc. grew its holdings in Immune Design Corp. by 2.1% during the second quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock valued at $19,281,000 after purchasing an additional 40,010 shares during the period. Wells Fargo & Company MN grew its holdings in Immune Design Corp. by 46.9% during the second quarter. Wells Fargo & Company MN now owns 218,700 shares of the biotechnology company’s stock valued at $2,132,000 after purchasing an additional 69,813 shares during the period. Finally, Bain Capital Public Equity Management LLC grew its holdings in Immune Design Corp. by 393.1% during the second quarter. Bain Capital Public Equity Management LLC now owns 389,400 shares of the biotechnology company’s stock valued at $3,797,000 after purchasing an additional 310,433 shares during the period. 51.76% of the stock is owned by institutional investors and hedge funds.

In other Immune Design Corp. news, Director Franklin M. Berger bought 25,000 shares of Immune Design Corp. stock in a transaction dated Wednesday, October 25th. The stock was bought at an average cost of $4.26 per share, with a total value of $106,500.00. Following the completion of the acquisition, the director now directly owns 50,000 shares in the company, valued at approximately $213,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Leo Guthart bought 10,000 shares of Immune Design Corp. stock in a transaction dated Monday, September 18th. The stock was acquired at an average cost of $9.70 per share, with a total value of $97,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 5,300,000 shares of company stock valued at $21,874,900. 20.70% of the stock is currently owned by corporate insiders.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Earnings History and Estimates for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.